SCHEMBL4435666

SCHEMBL4435666

CN1C(=O)C(Cc2ccccc2)C(=O)N(C)C1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.72
MEN1 O00255 5/20 0.72
KDM4C Q9H3R0 4/20 0.72
MAPT P10636 10/20 0.62
ALDH1A1 P00352 9/20 0.62
HSD17B10 Q99714 7/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
KDM4A O75164 2/20 0.62
GAA P10253 4/20 0.61
THRB P10828 2/20 0.61
RECQL P46063 1/20 0.61
EP300 Q09472 1/20 0.61
POLB P06746 3/20 0.58
USP2 O75604 2/20 0.58
ALOX15 P16050 1/20 0.58
CACNA1B Q00975 1/20 0.55
APBA1 Q02410 1/20 0.55
CES2 O00748 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HPGD P15428 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17717914 0.90 ALDH1A1 (0.72) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL17358747 0.90 KMT2A (0.65) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL15978122 0.87 MAPT (0.60) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL17358734 0.87 KDM4C (0.62) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL17717935 0.86 KMT2A (0.61) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL17717913 0.83 KMT2A (0.62) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL15978256 0.81 ALDH1A1 (0.62) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL31424239 0.81 ALDH1A1 (0.62) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL28013429 0.81 KMT2A (0.52) KMT2AMEN1KDM4CMAPTALDH1A1
SCHEMBL17294178 0.81 ALDH1A1 (0.62) KMT2AMEN1KDM4CMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108912057-A A method of barbituric acid derivatives are replaced by amine catalytic air oxidation green syt 5- hydroxyl -5- alkyl two 河南大学 2018-11-30 CN claimed
EP-2081576-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES Taro Pharmaceuticals North America, Inc. (KY) 2009-07-29 EP claimed
WO-2008066704-A2 METHOD OF IMPROVING BIOAVAILABILITY FOR NON-SEDATING BARBITURATES TARO PHARMACEUTICALS NORTH AMERICA, INC. (KY) 2008-06-05 WO claimed
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-06-05 US claimed
CN-1291720-C Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2006-12-27 CN claimed
EP-1485101-A4 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMA IND (IL) 2006-04-12 EP claimed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US claimed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN claimed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP claimed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US claimed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO claimed
US-20240343848-A1 FREE-RADICALLY POLYMERIZABLE COMPOSITION, METHOD OF POLYMERIZING THE SAME, AND POLYMERIZED COMPOSITION 3M INNOVATIVE PROPERTIES COMPANY 2024-10-17 US disclosed
EP-4423191-A1 PHOTOPOLYMERIZABLE COMPOSITION, METHODS OF BONDING AND SEALING, AND AT LEAST PARTIALLY POLYMERIZED COMPOSITION 3M Innovative Properties Company (US) 2024-09-04 EP disclosed
CN-117836333-A Free radically polymerizable composition, method of polymerization, and polymerized composition 3M创新有限公司 2024-04-05 CN disclosed
US-11897977-B2 Photolabile barbiturate compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2024-02-13 US disclosed
US-6939873-B2 Non-sedating barbituric acid derivatives TARO PHARMACEUTICALS INDUSTRIES LIMITED (IL) 2005-09-06 US disclosed
CN-1625401-A Non-sedating barbituric acid derivatives TARO PHARMA IND (IL) 2005-06-08 CN disclosed
EP-1485101-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES Taro Pharmaceutical Industries Limited (IL) 2004-12-15 EP disclosed
US-20030187005-A1 Non-sedating barbituric acid derivatives TARO PHARMACEUTICAL INDUSTRIES LTD. 2003-10-02 US disclosed
WO-2003063872-A1 NON-SEDATING BARBITURIC ACID DERIVATIVES TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132529-A1 Method of improving bioavailability for non-sedating barbiturates MTNR1B, GABRB3, GABBR1 KMT2A 1862/4885MEN1 1891/4885KDM4C 1141/4885
US-20030187005-A1 Non-sedating barbituric acid derivatives GABRA5, GABRA1, GABRA3 KMT2A 1865/4885MEN1 3949/4885KDM4C 3945/4885
US-11897977-B2 Photolabile barbiturate compounds PPOX, CBR1, CBR3 KMT2A 3332/4885MEN1 4096/4885KDM4C 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.